Xsure is a decentralized risk management platform that facilitates real-time communication between insurance providers and the end customer. With the help of machine learning and blockchain trust-less governance technologies we have managed to eliminate third parties from the whole insurance life-cycle and turn it into a dynamic process instead of a static one.

Adrealm aims to rebuild the digital advertising ecosystem and cultivate a self-sustaining open ecosystem for all participants to achieve advertising efficiency. Built on ERC-20 standard of the Ethereum platform, Adrealm connects advertisers, service providers, content publishers, developers etc on its decentralized public ledger ensuring privacy and no third-party management of data. Thanks to its three-tier architecture made of an on-chain layer, off-chain layer, and a service layer, speed and efficiency can be guaranteed and the industry pain-points such as fraud, low-quality ads, and data leakage can be overcome. Adrealm relies on a particular consensus mechanism called Proof of Valid Traffic (PoVT) that makes high-quality ads and traffic the fundamental criteria for the operational success of transactions.

Pharmeum is the world's first blockchain-based prescription platform with AI health analytics, which is currently working alongside the National Health Service (NHS) in England. The Pharmeum platform is an inter-operable, decentralised, digital prescription platform running over an intelligent neural network. Empowering patients’ ownership of their medication history, and enabling affordable access to healthcare globally. Medical errors and late diagnoses are minimised by using a permissioned blockchain integrated with artificial intelligence. Pharmeum is an advanced, digitised, health eco-system.The Pharmeum blockchain will improve medicine affordability, minimise errors, and create frictionless, quality care for patients.

DATA is a blockchain project initiated and governed by Blockchain Data Foundation Limited ("Blockchain Data Foundation", or BDF from hereafter), a company limited by guarantee to be incorporated in Singapore and governed in a not-for-profit manner. This project is being developed in collaboration with Yomob International Co., Ltd. ("Yomob"), a mobile monetization-as-a-service company.

We intend to develop MeconCash into a platform that allows user’s assets to be transferred and traded between different types of services by integrating point reward systems, contents purchase, and settlement, which are currently operated separately between existing services and those under development. To that end, we will build the reward and settlement system, develop the API to connect it with other services, and build an ecosystem that can be used in the on- and off-line real economy. All this will ensure the usability, connectivity, and sustainability of MeconCash. We will develop a variety of mobile-based applications, games, and contents on the platform and link it with such services as online marketplaces where users can purchase products. The reward system used by a service generally invalidates the rewards owned by users when the service is terminated. MeconCash, however, can transform the rewards obtained from using our services into valuable assets. As such, users will be able to fulfill the demand for new services with MeconCash even when the services they use are terminated, make transactions between them, and use the assets in the real economy. We will stabilize the MeconCash ecosystem by developing new blockchain-based businesses and linking it with external services which already exists. Additionally, MeconCash will be available in 70% of ATMs in Korea so that users can directly withdraw MeconCash to fiat money.

The Invictus Margin Lending Fund offers investors the ability to take advantage of the volatile nature of the cryptocurrency market without risking direct exposure. The fund aims to maximize interest income on USD and USD equivalents with zero anticipated drawdown risk by taking dollar-based positions on margin lending platforms.